Differential diagnosis of renal tumors with clear cytoplasm: Clinical relevance of renal tumor subclassification in the era of targeted therapies and personalized medicine

Archives of Pathology and Laboratory Medicine

Volumn 137, Issue 4, 2013, Pages 467-480

  Goyal, Rajen ^a   Gersbach, Elizabeth ^a   Yang, Ximing J ^a   Rohan, Stephen M ^a  

^a NORTHWESTERN MEMORIAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR MARKER;

ADENOCARCINOMA; ADRENAL CORTEX TUMOR; ANGIOMYOLIPOMA; CLASSIFICATION; DIFFERENTIAL DIAGNOSIS; EPITHELIOID CELL; GENE TRANSLOCATION; GENETIC MARKER; HUMAN; KIDNEY CARCINOMA; KIDNEY TUMOR; METABOLISM; MOLECULARLY TARGETED THERAPY; ONCOCYTOMA; PATHOLOGY; PERSONALIZED MEDICINE; REVIEW; WORLD HEALTH ORGANIZATION;

ADENOCARCINOMA, PAPILLARY; ADENOMA, OXYPHILIC; ADRENAL CORTEX NEOPLASMS; ANGIOMYOLIPOMA; CARCINOMA, RENAL CELL; DIAGNOSIS, DIFFERENTIAL; EPITHELIOID CELLS; GENETIC MARKERS; HUMANS; INDIVIDUALIZED MEDICINE; KIDNEY NEOPLASMS; MOLECULAR TARGETED THERAPY; TRANSLOCATION, GENETIC; TUMOR MARKERS, BIOLOGICAL; WORLD HEALTH ORGANIZATION;

EID: 84876583196     PISSN: 00039985     EISSN: 15432165     Source Type: Journal    
DOI: 10.5858/arpa.2012-0085-RA     Document Type: Review

References (127)

1. Delahunt B, Eble JN. History of the development of the classification of renal cell neoplasia. Clin Lab Med. 2005;25(2):231-246. (Pubitemid 40545817)
2. Eble JN, Togashi K, Pisani P. Renal Cell Carcinoma. In: Eble JN, Sauter G, Epstein JI, Sesterhenn IA, eds. Pathology and Genetics of Tumours of the Urinary System and Male Genital Organs. Lyon, France: IARC Press; 2004:9-87.
3. Reuter VE, Tickoo, SK. Adult renal tumors. In: Mills SE, Carter D, Greenson JK, Reuter VE, Stoler MH, eds. Sternberg's Diagnostic Surgical Pathology. Vol 2. 5th ed. Philadelphia, PA: Lippincott Williams & Wilkins; 2010:1758-1798.
4. Frank I, Blute ML, Cheville JC, Lohse CM, Weaver AL, Zincke H. Solid renal tumors: an analysis of pathological features related to tumor size. J Urol. 2003;170(6, pt 1):2217-2220. (Pubitemid 37413960)
5. Thompson RH, Kurta JM, Kaag M, et al. Tumor size is associated with malignant potential in renal cell carcinoma cases. J Urol. 2009;181(5):2033- 2036.
6. Lane BR, Abouassaly R, Gao T, et al. Active treatment of localized renal tumors may not impact overall survival in patients aged 75 years or older. Cancer. 2010;116(13):3119-3126.
7. Sun M, Trinh QD, Bianchi M, et al. A non-cancer-related survival benefit is associated with partial nephrectomy. Eur Urol. 2012;61(4):725-731.
8. Chawla SN, Crispen PL, Hanlon AL, Greenberg RE, Chen DY, Uzzo RG. The natural history of observed enhancing renal masses: meta-analysis and review of the world literature. J Urol. 2006;175(2):425-431. (Pubitemid 43067318)
9. Sun M, Abdollah F, Bianchi M, et al. Treatment management of small renal masses in the 21st century: a paradigm shift [published online ahead of print February 10, 2012]. Ann Surg Oncol. doi:10.1245/s10434-012-2247-0.
10. Rini BI, Campbell SC, Escudier B. Renal cell carcinoma. Lancet. 2009; 373(9669):1119-1132.
11. Molina AM, Feldman DR, Ginsberg MS, et al. Phase II trial of sunitinib in patients with metastatic non-clear cell renal cell carcinoma. Invest New Drugs. 2012;30(1):335-340.
12. Drucker BJ. Renal cell carcinoma: current status and future prospects. Cancer Treat Rev. 2005;31(7):536-545. (Pubitemid 41614811)
13. Santos N, Wenger JB, Havre P, et al. Combination therapy for renal cell cancer: what are possible options? Oncology. 2011;81(3-4):220-229.
14. Foster K, Prowse A, van den Berg A, et al. Somatic mutations of the von Hippel-Lindau disease tumour suppressor gene in non-familial clear cell renal carcinoma. Hum Mol Genet. 1994;3(12):2169-2173.
15. Seizinger BR, Rouleau GA, Ozelius LJ, et al. Von Hippel-Lindau disease maps to the region of chromosome 3 associated with renal cell carcinoma. Nature. 1988;332(6161):268-269. (Pubitemid 18076658)
16. Latif F, Tory K, Gnarra J, et al. Identification of the von Hippel-Lindau disease tumor suppressor gene. Science. 1993;260(5112):1317-1320. (Pubitemid 23231974)
17. Bitting RL, Madden J, Armstrong AJ. Therapy for non-clear cell histologies in renal cancer. Curr Clin Pharmacol. 2011;6(3):169-180.
18. Storkel S, Eble JN, Adlakha K, et al. Classification of renal cell carcinoma: Workgroup No. 1, Union Internationale Contre le Cancer (UICC) and the American Joint Committee on Cancer (AJCC). Cancer. 1997;80(5):987-989.
19. Amin MB, Tamboli P, Javidan J, et al. Prognostic impact of histologic subtyping of adult renal epithelial neoplasms: an experience of 405 cases. Am J Surg Pathol. 2002;26(3):281-291. (Pubitemid 34184451)
20. MacLennan GT, Cheng, L. Neoplasms of the kidney. In: Bostwik DG, Cheng L, eds. Urologic Surgical Pathology. 2nd ed. London, United Kingdom: Mosby Elsevier; 2008;77-171.
21. Kim SP, Weight CJ, Leibovich BC, et al. Outcomes and clinicopathologic variables associated with late recurrence after nephrectomy for localized renal cell carcinoma. Urology. 2011;78(5):1101-1106.
22. Bonsib SM. T2 clear cell renal cell carcinoma is a rare entity: a study of 120 clear cell renal cell carcinomas [discussion in J Urol. 2005;174(4, pt 1): 1202].
23. J Urol. 2005;174(4, pt 1):1199-1202.
24. de Peralta-Venturina M, Moch H, Amin M, et al. Sarcomatoid differentiation in renal cell carcinoma: a study of 101 cases. Am J Surg Pathol. 2001;25(3):275-284. (Pubitemid 32174196)
25. Fuhrman SA, Lasky LC, Limas C. Prognostic significance of morphologic parameters in renal cell carcinoma. Am J Surg Pathol. 1982;6(7):655-663. (Pubitemid 13234762)
26. Varela I, Tarpey P, Raine K, et al. Exome sequencing identifies frequent mutation of the SWI/SNF complex gene PBRM1 in renal carcinoma. Nature. 2011;469(7331):539-542.
27. Huebner K. Tumor suppressors on 3p: a neoclassic quartet. Proc Natl Acad Sci U S A. 2001;98(26):14763-14765. (Pubitemid 34013917)
28. Dreijerink K, Braga E, Kuzmin I, et al. The candidate tumor suppressor gene, RASSF1A, from human chromosome 3p21.3 is involved in kidney tumorigenesis. Proc Natl Acad Sci U S A. 2001;98(13):7504-7509. (Pubitemid 32567978)
29. Sukosd F, Kuroda N, Beothe T, Kaur AP, Kovacs G. Deletion of chromosome 3p14.2-p25 involving the VHL and FHIT genes in conventional renal cell carcinoma. Cancer Res. 2003;63(2):455-457. (Pubitemid 36152507)
30. Nickerson ML, Jaeger E, Shi Y, et al. Improved identification of von Hippel-Lindau gene alterations in clear cell renal tumors. Clin Cancer Res. 2008; 14(15):4726-4734.
31. Kovacs G, Erlandsson R, Boldog F, et al. Consistent chromosome 3p deletion and loss of heterozygosity in renal cell carcinoma. Proc Natl Acad Sci U S A. 1988;85(5):1571-1575. (Pubitemid 18070801)
32. Maxwell PH, Wiesener MS, Chang GW, et al. The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis. Nature. 1999;399(6733):271-275. (Pubitemid 29246458)
33. Maxwell PH, Pugh CW, Ratcliffe PJ. The pVHL-hIF-1 system: a key mediator of oxygen homeostasis. Adv Exp Med Biol. 2001;502:365-376. (Pubitemid 34234067)
34. Grabmaier K, AdW, MC, Verhaegh GW, Schalken JA, Oosterwijk E. Strict regulation of CAIX(G250/MN) by HIF-1alpha in clear cell renal cell carcinoma. Oncogene. 2004;23(33):5624-5631. (Pubitemid 39093040)
35. Wiesener MS, Munchenhagen PM, Berger I, et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res. 2001;61(13):5215-5222. (Pubitemid 32681556)
36. Krieg M, Haas R, Brauch H, Acker T, Flamme I, Plate KH. Up-regulation of hypoxia-inducible factors HIF-1alpha and HIF-2alpha under normoxic conditions in renal carcinoma cells by von Hippel-Lindau tumor suppressor gene loss of function. Oncogene. 2000;19(48):5435-5443. (Pubitemid 32000910)
37. Gunaratnam L, Morley M, Franovic A, et al. Hypoxia inducible factor activates the transforming growth factor-alpha/epidermal growth factor receptor growth stimulatory pathway in VHL(-/-) renal cell carcinoma cells. J Biol Chem. 2003;278(45):44966-44974. (Pubitemid 37377256)
38. Hudson CC, Liu M, Chiang GG, et al. Regulation of hypoxia-inducible factor 1alpha expression and function by the mammalian target of rapamycin. Mol Cell Biol. 2002;22(20):7004-7014.
39. Thomas GV, Tran C, Mellinghoff IK, et al. Hypoxia-inducible factor determines sensitivity to inhibitors of mTOR in kidney cancer. Nat Med. 2006; 12(1):122-127. (Pubitemid 43050086)
40. Al-Ahmadie HA, Alden D, Fine SW, et al. Role of immunohistochemistry in the evaluation of needle core biopsies in adult renal cortical tumors: an ex vivo study. Am J Surg Pathol. 2011;35(7):949-961.
41. Tickoo SK, Alden D, Olgac S, et al. Immunohistochemical expression of hypoxia inducible factor-1alpha and its downstream molecules in sarcomatoid renal cell carcinoma. J Urol. 2007;177(4):1258-1263. (Pubitemid 46436019)
42. Wykoff CC, Beasley NJ, Watson PH, et al. Hypoxia-inducible expression of tumor-associated carbonic anhydrases. Cancer Res. 2000;60(24):7075-7083. (Pubitemid 32059187)
43. Goyal R, Zhu, B, Parimi, V, et al. Immunohistochemical (IHC) expression of carbonic anhydrase IX (CA9) in papillary (PRCC) and chromophobe (CHRCC) renal cell carcinoma is associated with necrosis. Mod Pathol. 2011;24(1S):194A.
44. Mancilla-Jimenez R, Stanley RJ, Blath RA. Papillary renal cell carcinoma: a clinical, radiologic, and pathologic study of 34 cases. Cancer. 1976;38(6): 2469-2480. (Pubitemid 8015883)
45. Ronnen EA, Kondagunta GV, Ishill N, et al. Treatment outcome for metastatic papillary renal cell carcinoma patients. Cancer. 2006;107(11):2617- 2621. (Pubitemid 44845616)
46. Delahunt B, Eble JN, McCredie MR, Bethwaite PB, Stewart JH, Bilous AM. Morphologic typing of papillary renal cell carcinoma: comparison of growth kinetics and patient survival in 66 cases. Hum Pathol. 2001;32(6):590-595. (Pubitemid 32601240)
47. Yang XJ, Tan MH, Kim HL, et al. A molecular classification of papillary renal cell carcinoma. Cancer Res. 2005;65(13):5628-5637. (Pubitemid 40911163)
48. Sukov WR, Lohse CM, Leibovich BC, Thompson RH, Cheville JC. Clinical and pathological features associated with prognosis in patients with papillary renal cell carcinoma. J Urol. 2012;187(1):54-59.
49. Delahunt B, Eble JN. Papillary renal cell carcinoma: a clinicopathologic and immunohistochemical study of 105 tumors. Mod Pathol. 1997;10(6):537- 544. (Pubitemid 27293491)
50. Amin MB, Corless CL, Renshaw AA, Tickoo SK, Kubus J, Schultz DS. Papillary (chromophil) renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 62 cases. Am J Surg Pathol. 1997;21(6):621-635. (Pubitemid 27265749)
51. Tickoo SK, Reuter VE. Differential diagnosis of renal tumors with papillary architecture. Adv Anat Pathol. 2011;18(2):120-132.
52. Gobbo S, Eble JN, Maclennan GT, et al. Renal cell carcinomas with papillary architecture and clear cell components: the utility of immunohistochemical and cytogenetical analyses in differential diagnosis. Am J Surg Pathol. 2008;32(12):1780-1786.
53. Mai KT, Faraji H, Desantis D, Robertson SJ, Belanger EC, Levac J. Renal cell carcinoma with mixed features of papillary and clear cell cytomorphology: a fluorescent in situ hybridization study. Virchows Arch. 2010;456(1):77-84.
54. Klatte T, Pantuck AJ, Said JW, et al. Cytogenetic and molecular tumor profiling for type 1 and type 2 papillary renal cell carcinoma. Clin Cancer Res. 2009;15(4):1162-1169.
55. Lager DJ, Huston BJ, Timmerman TG, Bonsib SM. Papillary renal tumors: morphologic, cytochemical, and genotypic features. Cancer. 1995;76(4):669- 673.
56. van Houwelingen KP, van Dijk BA, Hulsbergen-van de Kaa CA, et al. Prevalence of von Hippel-Lindau gene mutations in sporadic renal cell carcinoma: results from The Netherlands cohort study. BMC Cancer. 2005;5:57.
57. Sanders ME, Mick R, Tomaszewski JE, Barr FG. Unique patterns of allelic imbalance distinguish type 1 from type 2 sporadic papillary renal cell carcinoma. Am J Pathol. 2002;161(3):997-1005. (Pubitemid 34988387)
58. Velickovic M, Delahunt B, Storkel S, Grebem SK. VHL. and FHIT locus loss of heterozygosity is common in all renal cancer morphotypes but differs in pattern and prognostic significance. Cancer Res. 2001;61(12):4815-4819. (Pubitemid 32691896)
59. Kondo K, Yao M, Yoshida M, et al. Comprehensive mutational analysis of the VHL gene in sporadic renal cell carcinoma: relationship to clinicopathological parameters. Genes Chromosomes Cancer. 2002;34(1):58-68. (Pubitemid 34260597)
60. Rohan SM, Al-Ahmadie, HA, Fine, SW, et al Hypoxia inducible factor (HIF) pathway in papillary renal cell carcinoma: a tissue microarray based study. Mod Pathol. 2008;21(1S):178A.
61. Schmidt L, Junker K, Nakaigawa N, et al. Novel mutations of the MET protooncogene in papillary renal carcinomas. Oncogene. 1999;18(14):2343-2350. (Pubitemid 29192711)
62. Heng DY, Choueiri TK. Non-clear cell renal cancer: features and medical management. J Natl Compr Canc Netw. 2009;7(6):659-665.
63. Rubin MA, Zhou M, Dhanasekaran SM, et al. Alpha-methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer. JAMA. 2002; 287(13):1662-1670. (Pubitemid 34289218)
64. Tretiakova MS, Sahoo S, Takahashi M, et al. Expression of alphamethylacyl-CoA racemase in papillary renal cell carcinoma. Am J Surg Pathol. 2004;28(1):69-76. (Pubitemid 38031623)
65. Yang XJ, Zhou M, Hes O, et al. Tubulocystic carcinoma of the kidney: clinicopathologic and molecular characterization. Am J Surg Pathol. 2008;32(2): 177-187. (Pubitemid 351172131)
66. Tickoo SK, dePeralta-Venturina MN, Harik LR, et al. Spectrum of epithelial neoplasms in end-stage renal disease: an experience from 66 tumorbearing kidneys with emphasis on histologic patterns distinct from those in sporadic adult renal neoplasia. Am J Surg Pathol. 2006;30(2):141-153. (Pubitemid 43740182)
67. Langner C, Rupar G, Leibl S, et al. Alpha-methylacyl-CoA racemase (AMACR/P504S) protein expression in urothelial carcinoma of the upper urinary tract correlates with tumour progression. Virchows Arch. 2006;448(3):325-330. (Pubitemid 43357649)
68. Camparo P, Vasiliu V, Molinie V, et al. Renal translocation carcinomas: clinicopathologic, immunohistochemical, and gene expression profiling analysis of 31 cases with a review of the literature. Am J Surg Pathol. 2008;32(5):656-670. (Pubitemid 351600831)
69. Paner GP, Srigley JR, Radhakrishnan A, et al. Immunohistochemical analysis of mucinous tubular and spindle cell carcinoma and papillary renal cell carcinoma of the kidney: significant immunophenotypic overlap warrants diagnostic caution. Am J Surg Pathol. 2006;30(1):13-19. (Pubitemid 43740204)
70. Molinie V, Balaton A, Rotman S, et al. Alpha-methyl CoA racemase expression in renal cell carcinomas. Hum Pathol. 2006;37(6):698-703. (Pubitemid 43956536)
71. Mai KT, Kohler DM, Belanger EC, Robertson SJ, Wang D. Sporadic clear cell renal cell carcinoma with diffuse cytokeratin 7 immunoreactivity. Pathology. 2008;40(5):481-486. (Pubitemid 351950899)
72. Rohan SM, Xiao Y, Liang Y, et al. Clear-cell papillary renal cell carcinoma: molecular and immunohistochemical analysis with emphasis on the von Hippel-Lindau gene and hypoxia-inducible factor pathway-related proteins. Mod Pathol. 2011;24(9):1207-1220.
73. Skinnider BF, Folpe AL, Hennigar RA, et al. Distribution of cytokeratins and vimentin in adult renal neoplasms and normal renal tissue: potential utility of a cytokeratin antibody panel in the differential diagnosis of renal tumors. Am J Surg Pathol. 2005;29(6):747-754. (Pubitemid 40734424)
74. Al-Ahmadie HA, Alden D, Qin LX, et al. Carbonic anhydrase IX expression in clear cell renal cell carcinoma: an immunohistochemical study comparing 2 antibodies. Am J Surg Pathol. 2008;32(3):377-382. (Pubitemid 351398928)
75. Donato DP, Johnson MT, Yang XJ, Zynger DL. Expression of carbonic anhydrase IX in genitourinary and adrenal tumours. Histopathology. 2011;59(6): 1229-1239.
76. Thoenes W, Storkel S, Rumpelt HJ. Human chromophobe cell renal carcinoma. Virchows Arch B Cell Pathol Incl Mol Pathol. 1985;48(3):207-217. (Pubitemid 15095927)
77. Bonsib SM, Lager DJ. Chromophobe cell carcinoma: analysis of five cases. Am J Surg Pathol. 1990;14(3):260-267. (Pubitemid 20122228)
78. Thoenes W, Storkel S, Rumpelt HJ, Moll R, Baum HP, Werner S. Chromophobe cell renal carcinoma and its variants - a report on 32 cases. J Pathol. 1988;155(4):277-287.
79. Amin MB, Paner GP, Alvarado-Cabrero I, et al. Chromophobe renal cell carcinoma: histomorphologic characteristics and evaluation of conventional pathologic prognostic parameters in 145 cases. Am J Surg Pathol. 2008;32(12): 1822-1834.
80. Przybycin CG, Cronin AM, Darvishian F, et al. Chromophobe renal cell carcinoma: a clinicopathologic study of 203 tumors in 200 patients with primary resection at a single institution. Am J Surg Pathol. 2011;35(7):962-970.
81. Leibovich BC, Lohse CM, Crispen PL, et al. Histological subtype is an independent predictor of outcome for patients with renal cell carcinoma. J Urol. 2010;183(4):1309-1315.
82. Beck SD, Patel MI, Snyder ME, et al. Effect of papillary and chromophobe cell type on disease-free survival after nephrectomy for renal cell carcinoma. Ann Surg Oncol. 2004;11(1):71-77.
83. Abrahams NA, MacLennan GT, Khoury JD, et al. Chromophobe renal cell carcinoma: a comparative study of histological, immunohistochemical and ultrastructural features using high throughput tissue microarray. Histopathology. 2004;45(6):593-602. (Pubitemid 40029819)
84. Bugert P, Gaul C, Weber K, et al. Specific genetic changes of diagnostic importance in chromophobe renal cell carcinomas. Lab Invest. 1997;76(2):203- 208. (Pubitemid 27082063)
85. Kovacs A, Kovacs G. Low chromosome number in chromophobe renal cell carcinomas. Genes Chromosomes Cancer. 1992;4(3):267-268.
86. Toro JR, Wei MH, Glenn GM, et al. BHD mutations, clinical and molecular genetic investigations of Birt-Hogg-Dube syndrome: a new series of 50 families and a review of published reports. J Med Genet. 2008;45(6):321-331. (Pubitemid 351839472)
87. Pavlovich CP, Walther MM, Eyler RA, et al. Renal tumors in the Birt-Hogg-Dube syndrome. Am J Surg Pathol. 2002;26(12):1542-1552.
88. Baba M, Hong SB, Sharma N, et al. Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling. Proc Natl Acad Sci U S A. 2006;103(42):15552-15557. (Pubitemid 44625630)
89. Gad S, Lefevre SH, Khoo SK, et al. Mutations in BHD and TP53 genes, but not in HNF1beta gene, in a large series of sporadic chromophobe renal cell carcinoma. Br J Cancer. 2007;96(2):336-340. (Pubitemid 46160640)
90. Murakami T, Sano F, Huang Y, et al. Identification and characterization of Birt-Hogg-Dube associated renal carcinoma. J Pathol. 2007;211(5):524-531. (Pubitemid 46502428)
91. Woodward ER, Ricketts C, Killick P, et al. Familial non-VHL clear cell (conventional) renal cell carcinoma: clinical features, segregation analysis, and mutation analysis of FLCN. Clin Cancer Res. 2008;14(18):5925-5930.
92. Nagy A, Zoubakov D, Stupar Z, Kovacs G. Lack of mutation of the folliculin gene in sporadic chromophobe renal cell carcinoma and renal oncocytoma. Int J Cancer. 2004;109(3):472-475. (Pubitemid 38252780)
93. Choueiri TK, Plantade A, Elson P, et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma. J Clin Oncol. 2008;26(1):127-131.
94. Aydin H, Chen L, Cheng L, et al. Clear cell tubulopapillary renal cell carcinoma: a study of 36 distinctive low-grade epithelial tumors of the kidney. Am J Surg Pathol. 2010;34(11):1608-1621.
95. Gobbo S, Eble JN, Grignon DJ, et al. Clear cell papillary renal cell carcinoma: a distinct histopathologic and molecular genetic entity. Am J Surg Pathol. 2008;32(8):1239-1245.
96. Duan L, Youseff RF, Margulis V, et al. Clear cell papillary renal cell carcinoma: clinicopathologic, immunohistochemical, and molecular analysis. Mod Pathol. 2011;24(suppl):189A.
97. Lopez JI, Moreno V, Garcia H, et al. Renal cell carcinoma in young adults: a study of 130 cases and a review of previous series. Urol Int. 2010;84(3):292- 300.
98. Sailey CJ, Dvorakova M, Papadimitriou JC, Borin JF, Ali T, Parwani AV. Molecular, immunohistochemical, and ultrastructural characterization of clear cell papillary renal cell carcinoma. Mod Pathol. 2010;23(1S):216A.
99. Herrera LP, Hes O, Hirsch M, et al. Clear cell papillary renal cell carcinoma (Cp-RCC) not associated with end stage renal disease: clinicopathiologic analysis of 50 tumors confirming a novel subtype of renal cell carcinoma (rcc) occuring in a sporadic setting. Mod Pathol. 2011;2011;24:197A.
100. Song L, Lal P, Tomaszewski JE, Bing Z. Immunohistochemical study of clear cell papillary renal cell carcinoma. Mod Pathol. 2011;24(1S):208A.
101. Michal M, Hes O, Nemcova J, et al. Renal angiomyoadenomatous tumor: morphologic, immunohistochemical, and molecular genetic study of a distinct entity. Virchows Arch. 2009;454(1):89-99.
102. Behdad A, Monzon FA, Hes O, et al. Relationship between sporadic clear cell-papillary renal cell carcinoma (CP-RCC) and renal angiomyoadenomatous tumor (RAT) of the kidney: analysis by virtual-karyotyping, fluorescent in situ analysis and immunohistochemistry (IHC). Mod Pathol. 2011;24(1S):179A.
103. Adam J, Couturier J, Molinie V, Vieillefond A, Sibony M. Clear-cell papillary renal cell carcinoma: 24 cases of a distinct low-grade renal tumour and a comparative genomic hybridization array study of seven cases. Histopathology. 2011;58(7):1064-1071.
104. Brannon AR, Haake SM, Hacker KE, et al. Meta-analysis of clear cell renal cell carcinoma gene expression defines a variant subgroup and identifies gender influences on tumor biology. Eur Urol. 2012;61(2):258-268.
105. Tomlinson GE, Nisen PD, Timmons CF, Schneider NR. Cytogenetics of a renal cell carcinoma in a 17-month-old child: evidence for Xp11.2 as a recurring breakpoint. Cancer Genet Cytogenet. 1991;57(1):11-17.
106. de Jong B, Molenaar IM, Leeuw JA, Idenberg VJ, Oosterhuis JW. Cytogenetics of a renal adenocarcinoma in a 2-year-old child. Cancer Genet Cytogenet. 1986;21(2):165-169. (Pubitemid 16163323)
107. Argani P, Antonescu CR, Illei PB, et al. Primary renal neoplasms with the ASPL-TFE3 gene fusion of alveolar soft part sarcoma: a distinctive tumor entity previously included among renal cell carcinomas of children and adolescents. Am J Pathol. 2001;159(1):179-192. (Pubitemid 33704203)
108. Argani P, Hawkins A, Griffin CA, et al. A distinctive pediatric renal neoplasm characterized by epithelioid morphology, basement membrane production, focal HMB45 immunoreactivity, and t(6;11)(p21.1;q12) chromosome translocation. Am J Pathol. 2001;158(6):2089-2096. (Pubitemid 32545194)
109. Argani P, Olgac S, Tickoo SK, et al. Xp11 translocation renal cell carcinoma in adults: expanded clinical, pathologic, and genetic spectrum. Am J Surg Pathol. 2007;31(8):1149-1160. (Pubitemid 47207116)
110. Argani P, Ladanyi M. Translocation carcinomas of the kidney. Clin Lab Med. 2005;25(2):363-378. (Pubitemid 40545824)
111. Davis IJ, Hsi BL, Arroyo JD, et al. Cloning of an alpha-TFEB fusion in renal tumors harboring the t(6;11)(p21;q13) chromosome translocation. Proc Natl Acad Sci U S A. 2003;100(10):6051-6056. (Pubitemid 36576929)
112. Argani P, Lae M, Hutchinson B, et al. Renal carcinomas with the t(6; 11)(p21;q12): clinicopathologic features and demonstration of the specific alpha-TFEB gene fusion by immunohistochemistry, RT-PCR, and DNA PCR. Am J Surg Pathol. 2005;29(2):230-240. (Pubitemid 40170642)
113. Argani P, Lal P, Hutchinson B, Lui MY, Reuter VE, Ladanyi M. Aberrant nuclear immunoreactivity for TFE3 in neoplasms with TFE3 gene fusions: a sensitive and specific immunohistochemical assay. Am J Surg Pathol. 2003;27(6): 750-761. (Pubitemid 36617511)
114. Ross H, Argani P. Xp11 translocation renal cell carcinoma. Pathology. 2010;42(4):369-373.
115. Martignoni G, Pea M, Gobbo S, et al. Cathepsin-K immunoreactivity distinguishes MiTF/TFE family renal translocation carcinomas from other renal carcinomas. Mod Pathol. 2009;22(8):1016-1022.
116. Argani P, Hicks J, De Marzo AM, et al. Xp11 translocation renal cell carcinoma (RCC): extended immunohistochemical profile emphasizing novel RCC markers. Am J Surg Pathol. 2010;34(9):1295-1303.
117. Argani P, Tsuda M, Chen M-S, Edgar M, Ladanyi M. Overexpression of the MET receptor tyrosine kinase in tumors with TFE3 gene fusions. Mod Pathol. 2006;19(S1):297A.
118. Tsuda M, Davis IJ, Argani P, et al. TFE3 fusions activate MET signaling by transcriptional up-regulation, defining another class of tumors as candidates for therapeutic MET inhibition. Cancer Res. 2007;67(3):919-929.
119. Nese N, Martignoni G, Fletcher CD, et al. Pure epithelioid PEComas (socalled epithelioid angiomyolipoma) of the kidney: a clinicopathologic study of 41 cases - detailed assessment of morphology and risk stratification. Am J Surg Pathol. 2011;35(2):161-176.
120. Aydin H, Magi-Galluzzi C, Lane BR, et al. Renal angiomyolipoma: clinicopathologic study of 194 cases with emphasis on the epithelioid histology and tuberous sclerosis association. Am J Surg Pathol. 2009;33(2):289-297.
121. He W, Cheville JC, Sadow PM, et al. Pathologic characteristics and clinical outcome of renal epithelioid angiomyolipoma: a multi-unstitutional experience based on primary tumor resections. Mod Pathol. 2011;24(S1):196A.
122. Wolff N, Kabbani W, Bradley T, Raj G, Watumull L, Brugarolas J. Sirolimus and temsirolimus for epithelioid angiomyolipoma. J Clin Oncol. 2010; 28(5):e65-e68.
123. Reuter VE. The pathology of renal epithelial neoplasms. Semin Oncol. 2006;33(5):534-543. (Pubitemid 44511979)
124. Murphy D, Grignon DJ, Perlman EJ. In: Tumors of the Kidney, Bladder, and Urinary Structures. Washington, DC: American Registry of Pathology; 2004; 149-152. Atlas of Tumor Pathology. 4th series, fascicle 1.
125. Brunelli M, Gobbo S, Segala D, et al. Clear or basophilic type 1 papillary renal cell carcinoma-like cells occuring in the central fibrous scar of renal oncocytoma represent a potential diagnostic pitfall. Mod Pathol. 2010;23(1S): 182A.
126. Ye H, Yoon GS, Epstein JI. Intrarenal ectopic adrenal tissue and renaladrenal fusion: a report of nine cases. Mod Pathol. 2009;22(2):175-181.
127. Sangoi AR, Fujiwara M, West RB, et al. Immunohistochemical distinction of primary adrenal cortical lesions from metastatic clear cell renal cell carcinoma: a study of 248 cases. Am J Surg Pathol. 2011;35(5):678-686.